Shares of Simulations Plus, Inc. (NASDAQ:SLP – Get Free Report) have been given a consensus recommendation of “Hold” by the ten brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.00.
Several brokerages recently issued reports on SLP. Wall Street Zen upgraded Simulations Plus from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. TD Cowen reiterated a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Citigroup reissued a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. BTIG Research downgraded Simulations Plus from a “buy” rating to a “neutral” rating in a research report on Thursday, December 18th. Finally, Zacks Research lowered Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd.
Get Our Latest Stock Report on Simulations Plus
Institutional Investors Weigh In On Simulations Plus
Simulations Plus Trading Up 1.2%
NASDAQ:SLP opened at $11.96 on Thursday. The firm has a 50-day moving average price of $13.41 and a two-hundred day moving average price of $16.10. Simulations Plus has a twelve month low of $11.09 and a twelve month high of $36.45. The company has a market capitalization of $240.99 million, a P/E ratio of -3.74 and a beta of 1.18.
Simulations Plus (NASDAQ:SLP – Get Free Report) last announced its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.05). Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. The business had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.05 million. During the same period last year, the company earned $0.17 EPS. On average, equities research analysts predict that Simulations Plus will post 1.09 earnings per share for the current year.
About Simulations Plus
Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.
Read More
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.
